Medical Pharmacology: Adrenergic, Autonomic pharmacology

"The Neurobiology of Addiction The Reward Pathway"

Attribution: Merritt P The Neurobiology of Addiction The Reward Pathway (May 29, 2019) https://www.youtube.com/watch?v=x0uqQYhw6Es Paul Merritt https://www.youtube.com/@PaulMerritt

Dopamine I

**Dopamine Pathways, Antipsychotics and Extrapyramidal Syndromes**

Attribution: Dirty Medicine Dopamine Pathways, Antipsychotics, and EPS https://www.youtube.com/watch?v=wCtC3LN2Vfc Dirty Medicine Youtube Channel https://www.youtube.com/channel/UCZaDAUF7UEcRXIFvGZu3O9Q

Dopamine Overview
Dopamine
Dopamine β-hydroxylase catalyzes the conversion of dopamine to norepinephrine.⁴
Dopamine is an important CNS neurotransmitter and loss of dopaminergic projections in the basal ganglia is considered causative in Parkinson's disease.⁴

**Basal Ganglia**⁸⁹

"The basal ganglia comprises the caudate nucleus, the putamen and the globus pallidus, and forms part of the ‘extrapyramidal motor system’. The basal ganglia is involved in the control of movement. Abnormalities in this area of the brain can result in a variety of diseases, including Parkinson’s disease and Huntington’s disease."⁸²

Over 50% of CNS catecholamine content is due to dopamine.⁸¹
- Highest amounts are localized in the caudate nucleus (basal ganglia), central nucleus of the amygdala, the median eminence, and restricted frontal cortex fields.
Concerning dopaminergic pathways, emphasis has been placed on projections between dopamine containing substantia nigra nuclei and ventral tegmentum and their terminations in the stratum, limbic zones of the cerebral cortex and in other non-hippocampal limbic areas.



"Dopamine is transmitted via three major pathways: The first pathway extends from the substantia nigra to the caudate nucleus-putamen (neostratum) and is concerned with sensory stimuli and movement. The second pathway projects from the ventral tegmentum to the mesolimbic forebrain and is thought to be associated with cognitive, reward and emotional behavior. The third pathway, known as the tubero-infundibular system, is concerned with neuronal control of the hypothalamic-pituitary endocrine system."⁸²

Dopamine actions at the level of the cell depend both on dopamine receptor subtype expression and interactions of dopamine with other narrow transmitters at the same neural target cell.
- Outside the CNS, dopamine is synthesized in renal proximal tubule epithelial cells where dopamine promotes both natriuretic and diuretic actions.
  - Because dopamine is a substrate for catecholamine-O-methyltransferase (COMT) as well as for monoamine oxidase (MAO), oral administration is not effective.

Dopamine Receptors⁸¹

Initially two subtypes of dopamine receptors were identified: D₁ and D₂.

These receptors are G protein coupled.

D₁ receptors were found to couple to G_s and act to increase adenylyl cyclase catalytic activity.

D₂ receptors act via G_i and reduce adenylyl cyclase activity.

Molecular cloning studies later identified additional dopamine receptor subtypes.

One, D₅ appear similar to the D₁ dopamine receptor; whereas, D₃ and D₄ more closely resemble the D₂ form.

There appear to be two D₂ receptor isoforms, D₂ short (D_2s) and D2 long (D_2L), reflecting differing lengths of the third intracellular loop.

Proposed Structure of D₁-like Dopamine Receptor⁸⁴

G-protein generalized structure illustrating 7 transmembrane loops and dopamine extracellular and G-protein intracellular binding domains⁹²

Dopamine receptors are a member of one of four receptor superfamilies.

The superfamilies are described as follows:

(1) Ion channel linked (ionotropic) receptors;

(2) G-protein coupled (metabotropic) receptors;

(3) Kinase-linked receptors; and

(4) Gene transcription regulators.

Dopamine receptors belong to the second type, G-protein coupled receptors.

These receptors exhibit seven transmembrane spanning loops that are α-helical structures.

Dopamine association with its extracellular binding domain induces structural changes in the G-protein complex.

Inhibitory or stimulatory effects depend on the type of dopamine receptor activated.

For example, dopamine D₁ and D₅ receptors are associated with inhibitory G-proteins; however, dopamine D₂, D₃, and D₄ receptors are associated with stimulatory G-proteins.⁸⁵

G-Protein Cycle: note agonist binding (), dissociation-reassociation of α-β-δ G-protein subunits, and GDP-GTP cycling⁹³

Second messenger effects of dopamine receptor activation⁸⁶

Activation of D₁ receptors results in increased cAMP, increased Ca^{2 +} mobilization (via IP₃) and activation of protein kinase C (via diacylglycerol (DAG)).

Activation of D₂receptors decreases cAMP (G_i), increases K⁺, and decreases voltage-gated Ca^{2 +} currents.

α-adrenergic receptors are expressed both postsynaptically and presynaptically.

α₁ receptors populate mainly the postsynaptic membrane; whereas, α₂-adrenergic receptors are localized presynaptically and regulate norepinephrine release.

Some dopamine receptors are also localized presynaptically.

These presynaptic dopamine receptors are of the D₂variety.⁸⁶

Following dopamine release, some dopamine molecules, by diffusion, will interact with presynaptic D₂ receptors, a consequence of which is a decrease in dopaminergic release.

Additionally, D₂ receptor activation reduces presynaptic dopamine synthesis and the reduction in dopamine release may be accounted for by decrease in neuronal firing frequency.

Reduced dopamine synthesis itself is a cAMP-dependent process which downregulates (reduces) tyrosine hydroxylase activity.

The reduction in dopamine release and firing frequency are associated with changes in activity of Ca²⁺ and K⁺ channels.

Enhanced K⁺ channel conductance results in an increased hyperpolarizing current, which displaces membrane potential away from the threshold potential.

Reduced Ca²⁺ channel conductance decreases intracellular Ca²⁺ concentration which in turn decreases Ca²⁺-dependent dopamine release.

The association of a dopamine D₂ receptor antagonist at the binding domain prevents dissociation of the G protein complex and release of inhibitory G protein, G_i.

Therefore, subsequent effects on adenylyl cyclase activity, protein kinase C activity and ionic channel activity do not occur.⁸⁸

Various roles have been suggested for the five different dopamine receptor types; however, the common thread is either stimulation or inhibition of adenylyl cyclase.⁹⁴

A D₁-like brain receptor coupled to G_q/11 (a.k.a. G_q protein) when activated, may stimulate phospholipase C and promoting intracellular calcium release.⁹⁴

Unique pharmacological responses to dopamine agonists indicate that this D1-like receptor differs from the Gs/Golf system.

However, a heterotrimeric D₁-D₂dopamine receptor signaling complex and brain has been discovered.

This heterotrimeric structure is coupled to Gq/11 and necessitates agonist binding to both receptors for G protein activation with subsequent intracellular Ca²⁺ release.

Dopamine Receptor Complexes and Differing Cell Signalling^94a

Dopamine receptor distribution: D₁, D₅ versus D₂-D₄ differences with respect to localization and relative presence^86,87

The receptor subtypes are present in overlapping areas which is expectable given that D₁ receptors are found in the stratum, limbic system, thalamus and hypothalamus and that D₂ receptors are present not only at those sites but also in the pituitary gland. D₃ and D₄ receptors are also present in the limbic system.

The D₁ and D₂ receptors are notably present in the stratum as well as in the nucleus accumbens and olfactory tubercle.

D₂ receptors are notably expressed on anterior pituitary gland lactotrophs, regulating prolactin secretion.

D₂ receptors may play a role in schizophrenia given that many antipsychotic drugs exhibit affinity for this receptor type. D₃ and D₄ receptors which appear related to D₂ may also be involved in schizophrenia pathogenesis.

Elevated levels of D₃ are noted in the limbic system including the nucleus accumbens and olfactory tubercle; moreover, D₄ receptors are localized in frontal cortices, diencephalon and brainstem.

D₅ receptor types are expressed to a reduced extent, localized mainly in olfactory tubercle, hippocampus and hypothalamus.

Schizophrenia may be associated with dopaminergic hyperactivity and dopamine antagonists which are used as antipsychotic agents, including haloperidol, risperidone, and chlorpromazine, exhibit pharmacological antagonism at D₅-like receptors.

D₂ receptors may play a role in schizophrenia given that many antipsychotic drugs exhibit affinity for this receptor type.

Bromocriptine is an example of an agent clinically used to decrease prolactin secretion from pituitary tumors.

References
Hoffman, B.B and Lefkowitz, R.J, Catecholamines, Sympathomimetic Drugs, and Adrenergic Receptor Antagonists, In Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc.,1996, pp.199-242 Stoelting, R.K., "Sympathomimetics", in Pharmacology and Physiology in Anesthetic Practice, Lippincott-Raven Publishers, 1999, p. 260 Carotic Baroreceptors: CRRx: Mediine ReEnvisioned http://www.cvrx.com/patients/index.php?id=41 Westfall, TC and Westfall DP Adrenergic Agonists and Antagonists in Goodman and Gilman's The Pharmacological Basis of Therapeutics, eleventh editions, (Brunton LL, Lazo JS and Parker KL, eds), McGraw-Hill Medical Publishing Division, New York, 237-295, 2006. Catecholamine Biosynthesis: The Interactive Library; Edinformatics.com: http://www.edinformatics.com/interactive_molecules/info/adrenaline.htm . Standaert DG and Young AB Treatment of Central Nervous System Degenerative Disorders In Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc.,1996, pp536-537. Adrenergic Neuronal Diagram adapted from http://www.drugabuse.gov/pubs/teaching/Teaching4/Teaching.html Guanetidine (Ismelin™, brand name not available in the U.S.) pharmacology: Clinical Pharmacology, RxList: The Internet Drug Index, http://www.rxlist.com/ismelin-drug.htm . Williams FM and Turner TJ Adrenergic Pharmacology in Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 2nd Edition (Golan DE, Tashijan Jr AH, Armstrong EJ and Armstrong AW, eds) Wolters Kluwer-Lippincott Williams & Wilkins, Philadelphia, 129-144, 2008. Moss J and Glick D Autonomic Function in Anesthetic Pharmacology: Physiological Principles and Clinical Practice: A Companion to Miller's Anesthesia (Evers AS and Maze M, eds) Churchill Livingstone, Philadelphia, Chapter 14, 209-226, 2004. Presynaptic Proteins, Synaptic Vesicle Docking and Membrane Fusion, http://neuromuscular.wustl.edu/pathol/snare.htm#cachan, Neuromuscular Disease Center, Washington University, St. Louis, MO USA (http://neuromuscular.wustl.edu/index.html) Sudhof TC The Synaptic Vesicle Cycle, Annual Review of Neuroscience, July 200, Vol. 27, pp 509-547. Phenochomocytoma picture (http://health-pictures.com/pheochromocytoma.htm); Geneva Foundation of Medical Education and Research, Pheochromocytoma, http://www.gfmer.ch/selected_images_v2/detail_list.php?cat1=1&cat2=113&cat3=22&cat4=2&stype=n . Brown H, Goldberg PA, Selter JG, Cabin HS, Marieb NJ, Udelsman R and Setaro JF Hemorrhagic Pheochromocytoma Associated with Systemic Corticosteroid Therapy and Presenting as Myocardial Infarction with Severe Hypertension. Clinical Case Seminar, J Clin Endocrinol Metab 2005 90: 563-569. (http://jcem.endojournals.org/cgi/content/full/90/1/563). "Clevidine (Cleviprex) for IV Treatment of Severe Hypertension", Table 1. Some Parenteral Drugs for Hypertensive Emergencies. The Medical Letter^® on Drugs and Therapeutics, Volume 50 (Issue 1295) September 22, 2008. Katzung, BG Introduction to Autonomic Pharmacology (Section II: Autonomic Drugs) in: Basic and Clinical Pharmacology (10th edition), (Katzung BG, ed) McGraw-Hill Medical , New York, pp. 75-92, 2007. Sympathetic Nerve Pathway: Neuroeffector Junction ("Simplified diagram of a sympathetic neuroeffector junction displaying genes which may be involved"); PharmGKb modified slightly to highlight uptake1, uptake-2, uptake 1 block, and location of intravesicular norephinephrine synthesis. (Pharmacogenomics Knowledge Base). http://www.pharmgkb.org/search/pathway/neurotransmitter/neuroeffector.jsp . T.E. Klein, J.T. Chang, M.K. Cho, K.L. Easton, R. Fergerson, M. Hewett, Z. Lin, Y. Liu, S. Liu, D.E. Oliver, D.L. Rubin, F. Shafa, J.M. Stuart and R.B. Altman, "Integrating Genotype and Phenotype Information: An Overview of the PharmGKB Project" (220k PDF), The Pharmacogenomics Journal (2001) 1, 167-170. Tellioglu T, Robertson D (November 2001). "Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications". Expert Rev Mol Med 2001: 1–10. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V (Aug 1998). "Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta". J Biol Chem 273 (26): 15971–9. Amphoux A, Vialou V, Drescher E, Brüss M, Mannoury La Cour C, Rochat C, Millan MJ, Giros B, Bönisch H, Gautron S. (Jun 2006). "Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain.". Neuropharmacology 50 (8): 941–952. Bourne HR and von Zastrow M "Drug Receptors and Pharmacodyamics" Chapter 2 in Basic and Clinical Pharmacology (10th edition), (Katzung BG, ed) McGraw-Hill Medical , New York, pp. 17-27, 2007. Muller M Lecture Material Online: Lecture 6: "Cellular Communication" http://www.uic.edu/classes/bios/bios100/summer2003/lect06.htm. Bowman T and Jove R STAT Proteins and Cancer: From the Molecular Oncology Program at the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida http://www.moffitt.org/moffittapps/ccj/v6n6/dept6h.htm . Tong L, Warren TC, King J, Betageri R, Rose J, Jakes S (March 1996). "Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution". J. Mol. Biol. 256 (3): 601–10. Sadowski I, Stone JC, Pawson T (December 1986). "A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps". Mol. Cell. Biol. 6 (12): 4396–4408. Russell RB, Breed J, Barton GJ (June 1992). "Conservation analysis and structure prediction of the SH2 family of phosphotyrosine binding domains". FEBS Lett. 304 (1): 15–20. von Zastrow M and Bourne HR "Drug Receptors and Pharmacodynamics" Chapter 2 in Basic and Clinical Pharmacology (11th edition), (Katzung BG, Masters, SB and Trevor AJ, eds) McGraw-Hill Medical , New York, on-line version (Access Medicine) 2009. Powledge TM (2004) Nicotine as Therapy. PLoS Biol 2(11): e404. doi:10.1371/journal.pbio.0020404 (http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.0020404) Green T, Heinemann SF and Gusella JF Molecular Neurobiology and Genetics: Investigation of Neuron Function and Dysfunction (Review) Neuron, Vol. 20, 427-444, March, 1998 (Cell Press (c), 1998). Unwin N Nicotinic acetylcholine receptor at 9 Å resolution. J. Mol. Biol. 229, 1101-1124. Eyford, T Adenylyl cyclase http://proteopedia.org/wiki/index.php/Adenylyl_cyclase . 31 a. Hurley JH. Structure, mechanism, and regulation of mammalian adenylyl cyclase. J Biol Chem. 1999 Mar 19;274(12):7599-602. 31 b, Zhang G, Liu Y, Ruoho AE, Hurley JH. Structure of the adenylyl cyclase catalytic core. Nature. 1997 Mar 20;386(6622):247-53. Goodsell DS illustrator, The Scrips Research Institute, public domain work, http://en.wikipedia.org/wiki/Adenylate_cyclase . Ranganathan R, Ross E (1997). "PDZ domain proteins: scaffolds for signaling complexes.". Curr Biol 7 (12): R770–3 PDZ domain http://en.wikipedia.org/wiki/PDZ_domain Biaggioni I and Robertson D Adrenoceptor Agonists & Sympathomimetic Drugs (Chapter 9) in in Basic and Clinical Pharmacology (11th edition), (Katzung BG, Masters, SB and Trevor AJ, eds) McGraw-Hill Medical , New York, on-line version (Access Medicine) 2009. Korte E "PIP2 cleavage by PLC to release IP3 and DAG", public domain, http://en.wikipedia.org/wiki/File:PIP2_cleavage_to_IP3_and_DAG.jpg . McVary KT A review of combination therapy in patients with benign prostatic hyperplasia, Clinical Therapeutics 2007 29 (3): 387-398. Caine M The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986; 136: 1-4. Shapiro E Hartanto V and Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992; 21: 297-307. Brittsan AG and Kranias EG Review: Phosphlakmban and Cardiac Contractile Function. J. Mol Cell Cardiol 32. 2131-2139. Lomize A Phospholamban Pentamer, protein image from OPM database, public domain media (http://en.wikipedia.org/wiki/File:1zll_opm.gif) Foex P and Highan H. Myocardial Performance: Physiological Principles and Clinical Practice: A Companion to Miller's Anesthesia (Evers AS and Maze M, eds) Churchill Livingstone, Philadelphia, Chapter 14, 284-2285, 2004. 42(a) Weiss HR Effect of coronary artery occlusion on regional arterial and venous O₂ saturation, O₂ extraction, blood flow and O₂ consumption in the dog heart. Circulation Research 47(3) 400-407, September 1980. Khouri EM Gregg DE and Rayford CR Effect of exercise on cardiac output, left coronary flow and myocardial metabolism in the unanesthetized dog. Circulation Research 17(5) 327-437, November 1965. Epicardial Vessels: Gray's Anatomy, 20th U.S. edition of Gray's Anatomy of the Human Body, originally publishedin 1918, public domain. Beta-2 Adrenergic Receptor, figure public domain (http://en.wikipedia.org/wiki/File:2RH1.png); original crystallographic citations: 45 (a) Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC (2007). "High-resolution crystal structure of an engineered human β₂-adrenergic G protein-coupled receptor". Science 318 (5854): 1258–65. 45 (b) Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK (2007). "GPCR engineering yields high-resolution structural insights into β₂-adrenergic receptor function". Science 318 (5854): 1266–73. Westfall, TC and Westfall DP Neurotransmission: The Autonomic and Somatic Motor Nervous System in Goodman and Gilman's The Pharmacological Basis of Therapeutics, eleventh editions, (Brunton LL, Lazo JS and Parker KL, eds), McGraw-Hill Medical Publishing Division, New York, 137-181, 2006. Emorine LJ Marullo S Briend-Sutren MM Patey G Tate K Delavier-Klutchko C Strosberg AD Molecular characterization of the human β₃-adrenergic receptor. Science, Vol. 245, No. 4922, Sep. 8, 1989, pp. 1118-1121. Walston J Silver K Bogardus C Knowler W Celi FS Austin S Manning B Strosberg AD Stern MP Raben N Sorkin JD Roth J Shuldiner AR Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β₃-adrenergic receptor gene. New England J. of Medicine, Vol. 333 No. 6, August 10, 1995, pp. 343-347. Hoffman BB Adrenoceptor-Activating & Other Sympathomimetic Drugs in: Basic and Clinical Pharmacology (10th edition), (Katzung BG, ed) McGraw-Hill Medical , New York, pp. 121-140, 2007. Goodsell, DS, Tyrosine Hydroxylase, The Scripps Research Institute, public domain image, http://en.wikipedia.org/wiki/File:Tyrosine_Hydroxylase.png . Chemical Synapse, http://schools-wikipedia.org/wp/c/Chemical_synapse.htm . Frang H Cockcroft V Karskela T Scheinin M Marjamaki A Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors JBC, 276, 31279-31284, June 6, 2001. http://www.jbc.org/content/276/33/31279.full Barrett KE Barman SM Boitano S Brooks H "The Adrenal Medulla & Adrenal Cortex" in: Ganong's Review of Medical Physiology, 23e, Chapter 22, on-line version, 2010. Achermann JC and Jameson JL "Disorders of Sex Development" in Harrison's Principles of Internal Medicine (eds, Fauci AS Braunwald E Kasper DL Hauser SL Longo DL Jameson JL Loscalzo J), 17th edition, pp 2345-2346, 2008, McGraw-Hill Medical, New York. Goldenberg M Aranow H Jr Smith AA Faber M Pheochromocytoma and essential hypertensive vascular disease. Arch. Intern. Med. 86: 823-826, 1950. Carrim YO "The Cardiovascular system, heart muscle; The heart as a pump." http://samedical.blogspot.com/2010/08/heart-muscle-heart-as-pump.html . "Madhero88" "A graphical representation of the electrical conduction system of the heart showing the sinoatrial node, atrioventricular none, bundle of His, Purkinje fibers and Bachmann's bundle, http://en.wikipedia.org/wiki/File:ConductionsystemoftheheartwithouttheHeart.png . Ewy GA Cardiopulmonary and Cardiocerebral Resuscitation, Chapter 50, in Hurst's The Heart, 12th edition (eds, Fuster V O'Rourke RA Wash RA Poole-Wilson P; associate eds: King II SB Roberts R Nash IS Prystowsky EN; Editors of the online edition: senior editors: Walsh RA and Simon DI; associate Editors; Hoit BD Fang JC Costa M), 2008, on-line edition. 58a. American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation, 2005; 112 (Suppl IV): IV-1-IV-211. Mohrman DE and Heller LJ "Vascular Control" Chapter 7, in Cardiovascular Physiology, 6th edition, The McGraw-Hill Companies, Inc, 2006, on-line edition. Stoelting, RK and Dierdorf, SF, "Asthma" in Anesthesia and Co-Existing Disease, 4th edition, Chapter 14, pp 194-204, Churchill-Livingstone, Philadelphia, 2002 60a. Kingston, HGG, Hirshman, CA Perioperative management of the patient with asthma. Anesth Analg 1984; 63: 844-55. (second sourced from reference 1) Roisen, MF, "Anesthetic Implications of Concurrent Diseases" in Anesthesia, 5th edition, (Miller, R.D, editor), Chapter 25, pp 996-997, Churchill-Livingstone, Philadephia 2000. Barrett KE Barman SM Boitano S Brooks H "Endocrine Functions of the Pancreas & Regulation of Carbohydrate Metabolism" in: Ganong's Review of Medical Physiology, 23e, Chapter 21, on-line version, 2010. Narayanese and YassineMrabet, Citric acid cycle (Tricarboxylic acid cycle), public domain, GNUU Free Documentation License, http://en.wikipedia.org/wiki/Citric_acid_cycle . Elayat AA, el-Naggar MM, Tahir M (1995). "An immunocytochemical and morphometric study of the rat pancreatic islets". Journal of Anatomy 186 (Pt 3): 629–37. (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1167020/pdf/janat00134-0170.pdf) 64a. Islets of Langerhans; http://en.wikipedia.org/wiki/Islets_of_Langerhans Süß C Sukale J Solima M "light microscopy of a paraffin embedded mouse islet; labels: insulin green, glucagon red, nuclei blue" Solimena Lab, Med. Fac., University of Technology, Dresden, Germany. http://en.wikipedia.org/wiki/File:Mouse_islet_LM_SolimenaLab.jpg . http://en.wikipedia.org/wiki/File:PDB_3tgl_EBI.jpg courtesy: http://www.ebi.ac.uk/ Chapus C, Rovery M, Sarda L, Verger R (1988). "Minireview on pancreatic lipase and colipase". Biochimie 70 (9): 1223–1234. Barrett KE Barman SM Boitano S Brooks H "General Principles & Energy Production in Medical Physiology in: Ganong's Review of Medical Physiology, 23e, Chapter 1, on-line version, 2010. Austgen L and Bowen R "Brown Adipose Tissue" http://www.vivo.colostate.edu/hbooks/pathphys/misc_topics/brownfat.html . Ropper AH and Samuels MA "Ion Channel Disorders: The periodic paralyses and hereditary nondystrophic mytonias (Channelopathies) in Adams & Victor's Principles of Neurology, 9e, 2009, online edition. Estelle F Simons R Gu X and Simons KJ Epinephrine absorption in adults: Intramuscular versus subcutaneous injection J Allergy Clin Immunol 2001; 108: 871-873. Flavine Adenine Dinucleotide (FAD) public domain images http://en.wikipedia.org/wiki/Flavin_adenine_dinucleotide . Axelrod J (August 1957). "O-Methylation of Epinephrine and Other Catechols in vitro and in vivo". Science 126 (3270): 400–1. Entacapone PubMed Health http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000168 . Dopamine Degradation by "Neurotiker", public domain image, http://en.wikipedia.org/wiki/File:Dopamine_degradation.svg . Haggstrom M Breakdown of norepinephrine, public domain inkscape http://en.wikipedia.org/wiki/File:Noradrenaline_breakdown.svg . Fvasconcellos "Cartoon diagram of human catechol-O-methyl transferase (COMT) in complex with S-adenosyl methionine and 3,5-dinitrocatechol; public domain drawing. 77a. Rutherford K, Le Trong I, Stenkamp RE, Parson WW (June 2008). "Crystal structures of human 108V and 108M catechol O-methyltransferase". J Mol Biol 380 (1): 120–30, http://www.rcsb.org/pdb/explore/explore.do?structureId=3BWM . Stoelting, R.K., "Local Anesthetics", in Pharmacology and Physiology in Anesthetic Practice, Lippincott-Raven Publishers, 1999, pp 158-181. Parrmann C Decision Making and Local Anesthesia Dimensions of Dental Hygiene, October 2008; 6(10): 24. http://www.dimensionsofdentalhygiene.com/ddhright.aspx?id=2384 . Allwood MJ Cobbold AF and Ginsberg J. Peripheral vascular effects of noradrenaline, isopropylnoradrenaline, and dopamine. Br. Med. Bull., 1963, 19: 132-136. Bloom FE Neurotransmission and the Central Nervous System in Goodman and Gilman's The Pharmacological Basis of Therapeutics, eleventh editions, (Brunton LL, Lazo JS and Parker KL,eds)McGraw-Hill Medical Publishing Division, New York, 317-340 2006. The dopamine pathways in the brain, Lundbeck Institute, CNSforum, Educational Resources, Image Bank, http://www.cnsforum.com/imagebank/item/Neuro_path_DA/default.aspx . Diseases associated with abnormalities in the basal ganglia, Lundbeck Institute, CNSforum, Educational Resources, Image Bank, http://www.cnsforum.com/imagebank/item/brain_struc_bagang_ALZ/default.aspx . Factor SA and Weiner WJ Molecular Characterization of Dopamine Receptors in Parkinson's Disease: Diagnosis and Management http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=parkinsons&part=A2249 . Dopamine receptors-7- transmembrane spanning, G-protein coupled receptors, Lundbeck Institute, CNSforum, Educational Resources, Image Bank, http://www.cnsforum.com/imagebank/item/D_struc_level2/default.aspx . Standaert DG and Galanter JM Pharmacology of Dopaminergic Neurotransmission in Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 2nd Edition (Golan DE, Tashijan Jr AH, Armstrong EJ and Armstrong AW, eds) Wolters Kluwer-Lippincott Williams & Wilkins, Philadelphia, 185-206, 2008. Dopamine receptor subtypes, Lundbeck Institute, CNSforum, Educational Resources, Image Bank, http://www.cnsforum.com/imagebank/item/DA_rcpt_subtypes/default.aspx . D₂ receptor antagonist, Lundbeck Institute, CNSforum, Educational Resources, Image Bank, http://www.cnsforum.com/imagebank/item/hrl_rcpt_sys_DA2_antag/default.aspx . Henkel J Structure of the basal ganglia, including thalamus, globus paladus, substantia nigra and cerebellum, http://en.wikipedia.org/wiki/File:Basal_Ganglia_and_Related_Structures.svg . Dopamine and Serotonin pathways, http://en.wikipedia.org/wiki/File:Dopamineseratonin.png . Valeryns G-protein receptor http://en.wikipedia.org/wiki/File:7TM4_(GPCR).png Bensaccount G-protein coupled receptor http://en.wikipedia.org/wiki/File:7TM4_(GPCR).png . Jahnichen S Activation cycle of G-proteins by G-protein-coupled receptors, http://en.wikipedia.org/wiki/File:GPCR-Zyklus.png . Raashid AS So CH Kong MMC Furtak T El-Ghundi M Cheng R O'Dowd BF George SR D₁-D₂ dopamine receptor heterooligomers with unique pharmacology are couple to rapid activation of Gq/11 in the striatum. PNAM, January 9, 2007, 104(2): 654-659.94a 94a. Whitten L Receptor complexes link dopamine to long-term neuronal effects, NIDA notes 22(4) http://drugabuse.gov/NIDA_notes/NNvol22N4/Receptor.html .